Both InterMune Inc. (NASDAQ:ITMN) and Boehringer Ingelheim GmbH have reported forced vital capacity (FVC) data for their idiopathic pulmonary fibrosis products that compares the proportion of treated patients who experienced a meaningful decrease in lung function, a marker of disease progression, vs. placebo. "Meaningful" was defined as a 10% decrease in FVC compared to baseline. In the Phase III ASCEND trial, InterMune's Esbriet pirfenidone led to a 48% reduction in